Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life Sciences

Latest Information Update: 07 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; University of British Columbia
  • Class Diagnostic agents; Vaccines
  • Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Amyotrophic lateral sclerosis
  • Suspended Creutzfeldt-Jakob disease

Most Recent Events

  • 28 Mar 2017 Preclinical development in Amyotrophic lateral sclerosis and Alzheimer's disease is ongoing in Canada
  • 08 Oct 2015 ProMIS Neurosciences expands exclusive license agreement with the University of British Columbia to gain worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications and enhancements to ProMIS™ technology
  • 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top